Search

Displaying results 1201 - 1210 of 8195 in total
  1. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment

  2. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]

  3. Drug

    Pentostatin

    go.drugbank.com/drugs/DB00552
    ApprovedInvestigational

    A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosupp...

  4. Drug

    Dioxybenzone

    go.drugbank.com/drugs/DB11221
    ApprovedWithdrawn

    Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525]. … Dioxybenzone, or benzophenone-8, is an organic compound derived from [DB01878] that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays.

  5. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    Spesolimab is an interleukin-36 (IL-36) receptor antagonist.

  6. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    However, the use of these agents is associated with a risk for uncontrollable bleeding episodes that can lead to can cause serious or fatal bleeding. … of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation pathways [A35558] and remains catalytically inactive due

  7. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inducers
  8. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Aminacrine

    go.drugbank.com/drugs/DB11561
    Investigational

    A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.

  10. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. … [L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal